Should GLP-1 drugs be PBS-listed for PCOS? The case being made

A piece in Medical Republic published on 13 October asks a question that is both clinical and political: should women with PCOS receive access to GLP-1 receptor agonist medications through the Pharmaceutical Benefits Scheme?

The article — which is behind a professional paywall — reports that advocates are pushing for GLP-1s to be PBS-approved for the management of PCOS, sometimes referred to in newer literature as polyendocrine metabolic ovarian syndrome. It is a debate worth watching, particularly for the approximately one in ten Australian women of reproductive age living with the condition.

What PCOS actually is

PCOS is the most common hormonal condition in women of reproductive age. Its hallmarks are irregular ovulation, elevated androgens (male-type hormones), and polycystic-appearing ovaries on ultrasound. In practice, it presents across a wide spectrum: some women experience it primarily as irregular periods; others as difficulty conceiving; others as acne, excess hair growth, weight gain, and insulin resistance that substantially affects daily life.

The metabolic features of PCOS are clinically significant and often undertreated. Insulin resistance affects a majority of women with PCOS regardless of body weight, and it is associated with an elevated long-term risk of type 2 diabetes and cardiovascular disease. International PCOS guidelines developed by Monash University — endorsed by 37 organisations globally — identify weight management and lifestyle interventions as a core plank of treatment for women who are overweight, because even modest weight loss can meaningfully improve hormonal, metabolic, and reproductive outcomes.

The problem is that weight management in PCOS is genuinely harder than in women without the condition. The hormonal environment drives weight gain; the insulin resistance makes it easier to store fat and harder to lose it. Standard dietary and exercise interventions produce smaller effects and are harder to sustain. This is not a failure of effort — it is biology.

The GLP-1 argument

GLP-1 receptor agonists — medications like semaglutide — work by slowing gastric emptying, reducing appetite, and improving insulin sensitivity. In people with type 2 diabetes and in those meeting criteria for medically managed obesity, the PBS listings reflect a robust evidence base.

For PCOS specifically, the evidence is more limited in scale but directionally consistent. Studies have shown that GLP-1 medications improve weight, insulin resistance, androgens, and in some cases menstrual regularity in women with PCOS. These are meaningful outcomes for a condition that significantly affects quality of life, fertility, and long-term metabolic risk.

The advocates’ argument is straightforward: if weight management is a first-line treatment recommendation for PCOS, and if GLP-1 medications are the most effective weight management intervention currently available, then denying PBS access to women with PCOS — unless they also have diabetes or meet obesity criteria — is an access equity problem. Women with the resources to pay full price out of pocket can access these medicines; women without cannot.

What’s contested

The both-and here is real.

The evidence for GLP-1s in PCOS, while promising, mostly comes from shorter trials with smaller sample sizes than the obesity and diabetes studies that underpinned PBS listings. Most PCOS trials were not powered to assess hard endpoints like cardiovascular outcomes. The safety data in younger women of reproductive age — including the question of what happens if a woman conceives while on a GLP-1 — requires careful consideration that the guidelines and TGA labelling are still working through.

The PBS listing process requires a submission to the Pharmaceutical Benefits Advisory Committee (PBAC), which evaluates clinical and cost-effectiveness relative to alternatives. A positive outcome for PCOS would require a sponsor willing to make that submission, evidence that clears the committee’s threshold, and a defined and auditable clinical population. None of those conditions is straightforward.

There is also a prescribing-intent question. PCOS is managed predominantly in general practice and by specialists, and a PBS listing would substantially increase prescribing volume. Whether that additional prescribing reflects genuine clinical need or extends into populations unlikely to benefit requires the kind of real-world safety monitoring that gets built into any new listing.

2 cents

This debate reflects something true about PCOS management in Australia: the gap between what the evidence supports and what patients can actually access is wide, and it falls hardest on women in lower-income brackets.

The clinical case for GLP-1 access in PCOS is not a stretch — it follows from the same weight-management rationale the guidelines already endorse. The policy path is slower and requires a level of evidence the field is building toward, not quite at yet.

If you have PCOS and are managing weight with difficulty, this is a conversation worth having with your GP now. There may already be a pathway to access — and if there isn’t, your GP can help you understand what is available and what the options look like as this evolves.

Verdict: maybe — the clinical case is coherent and the access equity concern is legitimate; the evidence threshold for a new PBS listing has not yet been fully met.

---

Sources cited

1. Should women with PCOS get subsidised weight-loss drugs? — Medical Republic, 13 October 2026
2. PCOS — Jean Hailes for Women’s Health
3. International PCOS assessment and management guideline — Monash University MCHRI